Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
The acceleration of the vaccination plan due to the arrival in the country of AstraZeneca (more than 2 million doses arrived this week) is good news, in the context of the fight against coronavirus, but it has a dark side that reflects the mess that occurs in health.
This vaccine began to be applied without any kind of restriction or warning when in other countries, especially in Europe, it is administered with certain recommendations due to cases of thrombosis in people who received it.
France, Spain, UK, Italy, Netherlands, Sweden, Denmark are some of the examples where deaths have occurred as a result of this side effect, and they have decided to limit its use or, directly, suspend it.
Although there is no defined parameter, most fatal cases have been detected in women under the age of 60. For this reason, some governments have decided to provide this segment of the population with vaccines from other laboratories.
Even the European Medicines Agency (EMA) recognized the link between this vaccine and cases of thrombosis, although it considered that the number of episodes (a few hundred out of the millions of doses provided) did not warrant a drastic measure. and that the risk of not getting vaccinated was greater, in a health emergency, to the possibility of critical images such as those detected.
According to certain districts consulted in the country, the Ministry of Health of the Nation has not given, for the moment, any type of recommendation for its application in Argentina.
It is expected that in the coming days the National vaccination commission give some guidance on how to proceed with this vaccine. It is a technical body which advises the Government on the matter.
What is catching the attention of specialists is the delay in doing so, given the fact that the debate over the effects of the vaccine AstraZeneca, in the world, has already been several months.
During this time, the application was carried out without restrictions. In many neighborhoods, they are already starting to vaccinate those under 50, the age group most exposed to the consequences detected in Europe.
It is a very sensitive subject which shows a conceptual error of the vaccination plan. No one is saying stop giving but there has to be a warning for those who get this vaccine. Whenever there are adverse effects, they must be reported, said an infectious disease specialist who advises the Government.
We can recommend but we don’t make decisions. In Europe, it has been discouraged to apply it to people under 60 or 50, especially women, but also men. In these cases, it was reserved for the elderly and was replaced by vaccines from other laboratories for the higher risk segment. This is something that needs to be fixed quickly, he added.
The problem, in Argentinais that Sputnik began to be applied to the elderly, because they were the ones who were available, and the vaccination of the age group under 60 is facing, with a greater supply of AstraZeneca.
.
[ad_2]
Source link
